Evidence map›Paper›PMID 37827146›Full record

ArticleDementia and geriatric cognitive disorders2023

The Memory Alteration Test Is Correlated with Clinical, Cerebrospinal Fluid, and Brain Imaging Markers of Alzheimer Disease in Lima, Peru.

Nilton Custodio, Marco Malaga, Rosa Montesinos, Diego Chambergo-Michilot, Fiorella Baca, Juan Carlos Carbajal, Jose Carlos Huilca, Eder Herrera-Perez, David Lira, Monica M Diaz and 1 more

Open access · greenAbstract read
In one paragraph

Article in Dementia and geriatric cognitive disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Nilton CustodioServicio de Neurología, Instituto Peruano de Neurociencias, Lima, Peru.
Marco MalagaUnidad de Investigación, Instituto Peruano de Neurociencias, Lima, Peru, marcomalagaj@gmail.com.
Rosa MontesinosUnidad de diagnóstico de deterioro cognitivo y prevención de demencia, Instituto Peruano de Neurociencias, Lima, Peru.
Diego Chambergo-MichilotUnidad de Investigación, Instituto Peruano de Neurociencias, Lima, Peru.
Fiorella BacaUnidad de diagnóstico de deterioro cognitivo y prevención de demencia, Instituto Peruano de Neurociencias, Lima, Peru.
Juan Carlos CarbajalUnidad de diagnóstico de deterioro cognitivo y prevención de demencia, Instituto Peruano de Neurociencias, Lima, Peru.
Jose Carlos HuilcaUnidad de diagnóstico de deterioro cognitivo y prevención de demencia, Instituto Peruano de Neurociencias, Lima, Peru.
Eder Herrera-PerezUnidad de diagnóstico de deterioro cognitivo y prevención de demencia, Instituto Peruano de Neurociencias, Lima, Peru.
David LiraServicio de Neurología, Instituto Peruano de Neurociencias, Lima, Peru.
Monica M DiazDepartment of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Serggio LanataDepartment of Neurology, Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
Institute of Peruvian Studies · PEInstituto Nacional de Enfermedades Neoplásicas · PEUniversidad Científica del Sur · PEUniversidad San Ignacio de Loyola · PEUniversity of North Carolina at Chapel Hill · US

Funding

US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative ResearchR01AG057234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Claudia Duran-Aniotz, Agustin M. Ibanez · 2019 to 2026
$6.1M
Genetic and environmental risk factors in mestizos and indigenous populations of Peru: the role of Native component in Alzheimer's diseaseR56AG069118 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI TOSTO, GIUSEPPE · 2020 to 2020
$1.1M
Improving identification of HIV-associated neurocognitive disorder (HAND) in Latin America: A multimodal approach to HAND in PeruK23MH131466 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DIAZ, MONICA MARIA · 2022 to 2025
$790k
NIA NIH HHS R01 AG057234NIA NIH HHS R56 AG069118NIMH NIH HHS K23 MH131466
6 · The paper itself

Abstract

introductionAs disease-modifying therapies become available for Alzheimer's disease (AD), detection of AD in early stages of illness (mild cognitive impairment [MCI], early dementia) becomes increasingly important. Biomarkers for AD in low- and middle-income countries (LMICs) are costly and not widely available; hence, it is important to identify cognitive tests that correlate well with AD biomarker status. In this study, we evaluated the memory alteration test (M@T) to detect biomarker-proven AD and quantify its correlation with neurodegeneration and cerebrospinal fluid (CSF) AD biomarkers in a cohort of participants from Lima, Peru.

methodsThis is a secondary analysis of a cohort of 185 participants: 63 controls, 53 with amnestic MCI (aMCI), and 69 with dementia due to AD. Participants underwent testing with M@T and a gold standard neuropsychological battery. We measured total tau (t-tau), phosphorylated tau (p-tau), and beta-amyloid (β-amyloid) in CSF, and evaluated neurodegeneration via medial temporal atrophy score in MRI. We used receiver-operator curves to determine the discriminative capacity of the total M@T score and its subdomains. We used the Pearson coefficient to correlate M@T score and CSF biomarkers.

resultsThe M@T had an area under the curve (AUC) of 0.994 to discriminate between controls and cognitively impaired (aMCI or AD) patients, and an AUC of 0.98 to differentiate between aMCI and AD patients. Free-recall and cued recall had the highest AUCs of all subdomains. Total score was strongly correlated with t-tau (-0.77) and p-tau (-0.72), and moderately correlated with β-amyloid (0.66). The AUC for discrimination of neurodegeneration was 0.87.

conclusionThe M@T had excellent discrimination of aMCI and dementia due to AD. It was strongly correlated with CSF biomarkers and had good discrimination of neurodegeneration. In LMICs, the M@T may be a cost-effective screening tool for aMCI and dementia caused by AD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesBiomarkersBrainHumansNeuroimagingPeptide FragmentsPerutau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAlzheimer’s diseaseBiomarkersBrief cognitive testsMild cognitive impairment

Identifiers

PMID37827146
PMCPMC11214699
OpenAlexW4387581779

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.